Memorial Sloan Kettering Cancer Center’s Post

https://lnkd.in/eX8KYSrv one of the PIs for YIV-906 (Formerly PHY906/KD018 aka Huang Qin Tang - huang qin, shao yao, zhi gan cao and da zao) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

🔬 Adjuvant Chemotherapy for Stage II Colon Cancer: A Critical Review 🔬 1.0 #CME 📚 Authors: Sara Elena Rebuzzi, Guido Pesola, Valentino Martelli, Alberto Felice Sobrero In the management of stage II colon cancer, surgery alone has a high cure rate of about 80%, but the role of adjuvant chemotherapy remains debated, especially for patients with high-risk features like T4 tumors or insufficient nodal sampling. This study provides: A thorough review of existing trials on risk stratification and the therapeutic benefits of adjuvant chemotherapy. Quantification of the impact of various prognostic factors. A proposed decision algorithm to help guide clinical practice. 🔗 https://lnkd.in/dNu4jBxz #PhysicianInsights #MedicalPractice #ColonCancer #Oncology #MedicalResearch #CME #DoctorsUpdate

This month's Simon Says Expert Series session -- Ovarian Cancer: Understanding Risk Factors, Diagnosis & Treatment -- will be at 12 p.m. ET Thursday, Sept. 26. Submit your questions and register now: http://go.iu.edu/8qJQ. The fifth leading cause of cancer death in the United States, ovarian cancer is primarily diagnosed in postmenopausal women and currently there are no effective preventative screening tools. Once a diagnosis is made, surgery and chemotherapy are typically both needed for successful treatment. However, several advances in the treatment of ovarian cancer use precision genomics, which guides individualized treatment for patients. In this Simon Says session, gynecologic oncologists Lisa Landrum, MD, PhD, and Sharon Robertson, MD, MPH, will discuss risk factors for ovarian cancer as well as risk reduction strategies and recent advances in its treatment.

I'm thrilled to share my latest research titled “Survival Outcomes in Stage IV Gastric Cancer Patients with Krukenberg Tumors: A Systematic Review and Meta-Analysis” is now published in the Journal of Gastrointestinal Cancer. Our study examined survival outcomes for Stage IV gastric cancer patients with Krukenberg tumors, comparing standard chemotherapy, surgical resection, and combined treatments. Analyzing data from 1502 patients across 17 studies, we found that overall survival (OS) was 6.7 months with chemotherapy only, 12.8 months with surgery, and 16.2 months with combined treatments. These findings show that combining chemotherapy and surgery offers the best survival benefit. We hope this research contributes to more informed and patient-centric approaches in oncology. 🔗 [https://lnkd.in/dS4azDjm] #GastrointestinalCancer #KrukenbergTumors #OncologyResearch #SystematicReview #MetaAnalysis #CancerCare #SurvivalOutcomes

Benyi Li, M.D., Ph.D., professor of urologic surgery at KU School of Medicine and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense (DoD) to develop a short peptide-based therapy for prostate cancer patients. It is Dr. Li’s 8th prostate cancer project to be funded by the DoD in the last 20 years. “Our preliminary studies have identified a small peptide capable of triggering the breakdown of this protein in prostate cancer cells," Dr. Li said. "The aim of our project is to optimize this small peptide to enhance its drug-like properties, paving the way for a potential new treatment.” Learn more about the study: https://bit.ly/3TuRRo5

Radiation therapy can be incorporated at various stages and for different purposes during cancer treatment. Your healthcare team might suggest radiation therapy in the following scenarios: As a standalone treatment for cancer, known as primary therapy. Prior to surgery to reduce the size of the tumor, referred to as neoadjuvant therapy. After surgery to inhibit the growth of any residual cancer cells, termed adjuvant therapy. As a supplementary treatment alongside other therapies like chemotherapy to eliminate cancer cells. To alleviate symptoms stemming from advanced-stage cancer. #CairoRadiotherapyComplex

Transarterial radioembolization (TARE) with Yttrium-90 (Y-90) is an innovative and effective treatment approach for liver cancer, particularly hepatocellular carcinoma (HCC) and liver metastases. This minimally invasive procedure delivers high doses of radiation directly to liver tumors while sparing healthy liver tissue, offering a potent and targeted therapeutic option for patients who are not candidates for surgery or other local therapies. To explore the principles, clinical applications, and potential benefits of Y-90 TARE in liver cancer treatment: https://lnkd.in/d2fX6f6w #Yttrium90 #Radioembolization #LiverCancerTreatment #Y90Therapy #medwise #livercancer #livercancertreatment

We examined survival outcomes for Stage IV gastric cancer patients with Krukenberg tumors - Zouina Sarfraz, MBBS Junaid Anwar Ahmed Abdelhakeem, M.D Anwaar Saeed #Cancer #Chemotherapy #OncoDaily #Oncology #GastrointestinalCancer #KrukenbergTumors #OncologyResearch

Gastric cancer (GC) represents the fifth most frequently diagnosed cancer accounting for more than 1,000,000 new cases per year and about 760,000 deaths worldwide. Even though surgical resection with D2 lymphadenectomy is still the mainstay of curative therapy, the patient's prognosis remains overall poor due to the high incidence of advanced and inoperable disease at diagnosis, and the high percentage of progression after surgery. In this context, multimodal approaches and new diagnostic tools to achieve an earlier diagnosis are urgent to be developed. CONGRATULATIONS to Elena Andreucci and Alessio Biagioni on winning the ImmunoTools FlowISiAM-award https://lnkd.in/eqf7CFth Carbonic Anhydrase IX as a diagnostic and prognostic marker for chemoresistance onset in gastric adenocarcinoma cancer